Michael R. Sisak, The Associated Press

Michael R. Sisak

The Associated Press

New York, NY, United States

Contact Michael

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Local 12/WKRC-TV
  • wbaltv.com
  • wdsu
  • WTAE-TV Pittsburgh
  • KOCO-5 Oklahoma City
  • MyNBC5 (WPTZ)
  • WLWT.com
  • KMBC
  • WGAL
  • WESH 2 News
  • WISN 12 News
  • WXII 12 News
  • KCCI News
  • 16 WAPT News
  • KOAT.com
  • WPBF 25 News
  • WYFF News 4
  • KSBW Action News 8
  • WLKY
  • kcranews
  • KETV NewsWatch 7
  • WMTW TV
  • WVTM 13
  • 4029news
  • ABC News
  • WOKV News
  • 8News WRIC Richmond
  • Washington Post
  • Local 4 WDIV Detroit
  • Cashay
  • ABC 33/40 News
  • WKBN 27 First News
  • Pioneer Press
  • 8 News NOW
  • KVOA News 4 Tucson
  • Action News on 6abc
  • KAKE News
  • Boston.com
  • Casper Star-Tribune
  • The Sentinel
  • The Bismarck Tribune
  • The Post-Star
  • Southern Illinoisan
  • Globe Gazette
  • Sioux City Journal
  • The T&D
  • Rapid City Journal
  • Belfast Telegraph
  • WACH FOX
  • WDRB News
  • NEWS102.3 KRMG
  • KSN News Wichita
  • The Morning Call
  • Winnipeg Free Press
  • KOIN News
  • The Associated Press
  • KOMO News
  • KSNT News
  • WRAL NEWS in NC
  • WSAV News 3
  • ABC News 4
  • PottstownMercury
  • WPTV
  • FOX 8 New Orleans
  • KOTA Territory News
  • nbc15_madison
  • WMBFNews.com
  • FOX 12 Oregon KPTV
Past:
  • FOX19
  • WBRC FOX6 News
  • FOX Carolina News
  • KTXS News
  • WIS News 10
  • WHSVnews
  • Houston Chronicle
  • L.A. Daily News
  • WWMT-TV
  • KATU News
  • and more…

Recent articles by Michael:

'Pharma Bro' Shkreli ordered to return $64M, is barred from drug industry

NEW YORK (AP) - A federal judge on Friday ordered Martin Shkreli to return $64. 6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life. The ruling by U. S. District Judge Denise Cote came several weeks after a seven-day bench trial in December. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More

Martin Shkreli ordered to return $64 million in pharmaceutical drug profits

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More